McKesson Corporation (0JZU.L)
LSE - LSE Delayed price. Currency in USD
Add to watchlist
As of 07:08PM BST. Market open.
| Previous close | 609.39 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 400 |
| Market cap | 112.151B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 0.84 |
| EPS (TTM) | 7.23 |
| Earnings date | 31 July 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksMcKesson (MCK) Reaches 52-Week High: What's Aiding the Stock?
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.
ZacksMcKesson (MCK) Increases Despite Market Slip: Here's What You Need to Know
In the most recent trading session, McKesson (MCK) closed at $603.24, indicating a +0.05% shift from the previous trading day.
- Zacks
McKesson (MCK) Introduces FDA-Approved Prostate Cancer Drug
The availability of the FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients improved treatment options for prostate cancer.
© 2024 Yahoo. All rights reserved.